#Metformin RCT on 41% prevention of #LongCOVID with acute #COVID19 treatment is now published in @TheLancetInfDis at:
doi.org/10.1016/S1473-…
N=1126 with long term follow up (~5% lost by 9mo)
10.4% vs. 6.3% LC incidence.
Double blind RCT using identical matched placebo.
Cost $1
doi.org/10.1016/S1473-…
N=1126 with long term follow up (~5% lost by 9mo)
10.4% vs. 6.3% LC incidence.
Double blind RCT using identical matched placebo.
Cost $1
The distribution of symptoms reported over time was similar as others have found. The figure (a new additional from the original pre-print) displays the freq of symptoms reported over 9 months among those wih a long covid diagnosis vs. no diagnosis.
#LongCovid symptoms interfered with both the ability to work and affected leisure activities in about half of those with LC. This very, very slowly decreased over time.
As this was a 3x2 factorial randomized trial, we also looked at #ivermectin at median dose of 430 mcg/kg/d x3d and low-dose fluvoxamine.
Acute treatment of #COVID19 with either of these did not have any subsequent benefit for reducing #LongCovid
Acute treatment of #COVID19 with either of these did not have any subsequent benefit for reducing #LongCovid
For #ivermectin, there were not any particular subgroups who appeared to benefit for preventing #LongCovid. This is very null, no effect.
Similarly, we did not observe any benefit with low dose #fluvoxamine (50mg 2x/day) for preventing #LongCovid in the Covid-Out trial.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
